ClinicalTrials.gg
RecruitingNCT07616206Hybrid CATT1Updated Nov 10, 2026

Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems

A Phase 2 interventional study of Cadisegliatin 800 mg QD and Placebo in Type 1 Diabetes (T1D), sponsored by vTv Therapeutics. Recruiting at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by vTv Therapeutics · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Nov 10, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 191 open to participants now, 259 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.

Planned enrollment
614th of 1,242
40 · median 40
Started
2026
with 62 others
Phase 2
188 of 1,458
24 open now
Primary completion
2027-06
later than 132 of 258 live
Registered
1,436th of 1,458
by date

Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 614th largest by planned enrollment of the 1,242 interventional ones that give a count, is one of 63 that started in 2026, is one of 188 in phase 2, reaches primary completion later than 132 of the 258 other live ones, and was the 1,436th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

191 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:

185 more — sign in →

All 191 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, or all of them as a file.
02

Study summary

TTP399-206 is a Phase 2a multicenter double blind cross over randomized study of cadisegliatin in participants with T1D using hybrid closed loop systems to manage their diabetes. Participants using a hybrid closed loop insulin pump to manage their diabetes will be randomized to either receive blinded cadisegliatin 800 mg QD as an adjunctive therapy to their insulin treatment or placebo QD along with their insulin treatment. The trial begins with a screening period of up to 2 weeks, followed by a device training and insulin adjustment period of 1-2 weeks leading into the first double-blind treatment period of 6 weeks. There will then be a washout period of 2 weeks followed by the second double-blind treatment period of 6 weeks where the participants will cross-over to the treatment that they did not receive in the first treatment period.

Read the detailed description

TTP399-206 is a 20 week, Phase 2a trial designed to evaluate efficacy and safety of cadisegliatin in participants with T1D who are using hybrid closed loop (HCL) systems to manage their condition to gather preliminary data to understand how cadisegliatin performs in an HCL setting.

03

Conditions studied

  • Type 1 Diabetes (T1D)

Keywords

  • Hybrid Closed Loop
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants >= 18 years of age
  • Fasting C-peptide levels \<0.6 ng/ml
  • Average TIR \< 70% recorded on their personal CGM data collected over the past 7 days prior to Visit 1
  • Currently on a hybrid closed loop device for at least 3 months and willing to stay on the same model of pump device for study duration
  • Willing to wear a study provided CGM for study duration
  • Total ≤2×, and AST ≤3×ULN

Key Exclusion Criteria:

  • Have Type 2 Diabetes Mellitus (DM), monogenic diabetes, maturity-onset diabetes, other unusual or rare forms of DM, or diabetes resulting from a secondary disease.
  • Have been hospitalized for DKA within 3 months
  • Have uncontrolled hypothyroidism or hyperthyroidism
  • Have interval > 450 msec for males or > 470 msec for females
  • Have a personal or family history of long QT syndrome, Torsades de pointes, or other complex ventricular arrhythmias
  • Have persistent, uncontrolled hypertension
  • Have cardiovascular or cerebrovascular disease
  • Have proliferative retinopathy or maculopathy requiring acute treatment
  • Have a serious concomitant systemic disorder including but not limited to or active Hep B or Hep C
  • Have been diagnosed and/or treated for within 3 years
  • Have used any of the following medications within the specified time periods: any non-insulin anti-diabetic therapies (e.g.SGLT-2 inhibitors, GLP-1 receptor agonists, metformin, sulfonylureas, DPP-4 inhibitors, pramlintide, a-glucosidase inhibitors, or glucose dependent insulinotropic polypeptide agonists) within 30 days, antipsychotic medications (e.g. olanzapine, risperidone, clozapine, quetiapine, and haloperidol) within 30 days, systemic for ≥7 days for a temporary medical condition within 30 days,
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Cadisegliatin 800 mg QD, then Placebo

    If a participant is randomized to receive cadisegliatin 800 mg QD as an adjunctive therapy to their insulin treatment in the first double-blind treatment period of 6 weeks, there will then be a washout period of 2 weeks followed by the second double-blind treatment period of 6 weeks where the participant will cross-over to the placebo QD along with their insulin treatment

    Drug: Cadisegliatin 800 mg QD · Drug: Placebo

  • Experimental
    Placebo, then Cadisegliatin 800 mg QD

    If a participant is randomized to receive placebo QD along with their insulin treatment in the first double-blind treatment period of 6 weeks, there will then be a washout period of 2 weeks followed by the second double-blind treatment period of 6 weeks where the participant will cross-over to the cadisegliatin 800 mg QD as an adjunctive therapy to their insulin treatment

    Drug: Cadisegliatin 800 mg QD · Drug: Placebo

Interventions

  • Cadisegliatin is an orally bioavailable small-molecule glucokinase activator, adjunctive therapy to insulin

    Also known as: TTP399

  • DrugPlacebo

    Placebo (insulin alone)

06

What researchers measure

Primary outcomes

  1. To assess the change in Time in Range (TIR)

    Time in Range (TIR) based on study CGM in participants with T1D who are using hybrid closed loop systems on cadisegliatin vs placebo

    Time frame: last 2 weeks of the two 6-week treatment periods

Secondary outcomes

  1. CGM-based metric for glycemic control

    Time In Tight Range (TITR)

    Time frame: last 2 weeks of each treatment period

  2. CGM-based metric for glycemic control

    Time Above Range (TAR)

    Time frame: last 2 weeks of each treatment period

  3. CGM-based metric for glycemic control

    Time Below Range (TBR)

    Time frame: last 2 weeks of each treatment period

  4. CGM-based metric for glycemic control

    Glucose Management Indicator (GMI)

    Time frame: last 2 weeks of each treatment period

  5. CGM-based metric for glycemic control

    Glucose variability (GV)

    Time frame: last 2 weeks of each treatment period

  6. CGM-based metric for glycemic control

    Time in Range (TIR) \> 70%

    Time frame: last 2 weeks of each treatment period

  7. Change in glucose control after standardized mixed meal tolerance test (MMTT)

    Glucose Peak Plasma Concentration (Cmax) based on study CGM after standardized mixed meal tolerance test (MMTT)

    Time frame: 12 weeks

  8. Change in glucose control after standardized mixed meal tolerance test (MMTT)

    Glucose Area under the plasma concentration versus time curve (AUC) based on study CGM after standardized mixed meal tolerance test (MMTT)

    Time frame: 12 weeks

  9. To assess the change in Level 1, Level 2 , and Level 3 hypoglycemic incidence

    Number of events of Level 1 and Level 2 hypoglycemia as determined by CGM and Level 3 hypoglycemic events in participants with T1D who are using hybrid closed loop systems on cadisegliatin vs placebo

    Time frame: 12 weeks

  10. Assess incidence of Serious Adverse Events (SAEs)

    Number of Serious Adverse Events (SAEs)

    Time frame: 14 weeks

  11. Assess incidence of Treatment Emergent Adverse Events (TEAEs)

    Number of treatment emergent adverse events (TEAEs)

    Time frame: 14 weeks

  12. Assess incidence of Treatment Emergent Adverse Events (TEAEs) leading to discontinuation

    Number of treatment emergent adverse events (TEAEs) leading to discontinuation of study drug

    Time frame: 14 weeks

  13. Assess incidence of Adverse Events of Special Interest (AESIs)

    Number of adverse events of special interest (AESIs)

    Time frame: 14 weeks

  14. Change from baseline in average daily total insulin dose

    Change from baseline in average daily total insulin dose in units (IU) based on manual entry in eDiary records from participants with T1D who are using hybrid closed loop systems on cadisegliatin vs placebo

    Time frame: last week of the two 6-week treatment periods

07

Study locations

6 of 6 sites recruiting
  • Paradigm Clinical Research -Modesto
    Modesto, California 95355, United States
    Recruiting
    • Gopika Gangupantula, MD · Principal investigator
  • Paradigm Clinical Research Centers, LLC
    San Diego, California 92108, United States
    Recruiting
    • Schafer Boeder, MD · Principal investigator
  • Barbara Davis Center for Diabetes
    Aurora, Colorado 80045, United States
    Recruiting
    • Halis Kaan Akturk, MD · Principal investigator
  • Atlanta Diabetes Associates
    Atlanta, Georgia 30318, United States
    Recruiting
    • Bruce W Bode, MD · Principal investigator
  • UNC Eastowne Medical Office Building
    Chapel Hill, North Carolina 27514, United States
    Recruiting
    • Klara Klein, MD, PhD · Principal investigator
  • Texas Diabetes & Endocrinology, P.A.
    Austin, Texas 78731, United States
    Recruiting
    • Thomas Blevins, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jun 2027, 9 months after the start.

Of 51 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 33. This study's planned 9 months is below that.

Counting every sponsor, half of 134 studies reached it within 36 months; a quarter within 17 and three quarters within 63.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Sep 2026, on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2026
First posted
Jun 1, 2026
StartActual
Sep 29, 2026was Oct 2026
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 10, 2026
Sites
5 sites added. Atlanta Diabetes Associates is now Recruiting
Show 5 added (5 United States)
  • Paradigm Clinical Research -Modesto · Modesto, United States
  • Paradigm Clinical Research Centers, LLC · San Diego, United States
  • Barbara Davis Center for Diabetes · Aurora, United States
  • UNC Eastowne Medical Office Building · Chapel Hill, United States
  • Texas Diabetes & Endocrinology, P.A. · Austin, United States
Nov 10, 2026
Start date
Oct 2026→Sep 29, 2026 (actual)
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Not yet recruiting→Recruiting
    5 sites added. Atlanta Diabetes Associates is now Recruiting
    Show 5 added (5 United States)
    • Paradigm Clinical Research -Modesto · Modesto, United States
    • Paradigm Clinical Research Centers, LLC · San Diego, United States
    • Barbara Davis Center for Diabetes · Aurora, United States
    • UNC Eastowne Medical Office Building · Chapel Hill, United States
    • Texas Diabetes & Endocrinology, P.A. · Austin, United States
    Start date Oct 2026→Sep 29, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07616206
Lead sponsor
vTv Therapeutics
Responsible party
Sponsor
First posted
Jun 1, 2026
Start date
Sep 29, 2026
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Meaghan Marnell
Contact
clinicaltrials@vtvtherapeutics.com
(336) 888-0435
Maria Alba, MD
study director · vTv Therapeutics LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TTP399

Start the discussion